THYROCARE TECH LTD
THYROCARE · Hospitals · NSE
₹388
Current Market Price
Fair Value (DCF)
₹423
Margin of Safety
+8.9%
Updated 4h ago
YieldIQ Score
70/100
Piotroski F-Score
8/9
Economic Moat
Wide
Confidence
79%
ROE
—
Debt/Equity
0.05
WACC
11.1%
Market Cap
₹6,178 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
26.0%
Return on capital employed
EV / EBITDA
25.5×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
48.7×
EBIT covers interest
Current Ratio
2.77×
Short-term liquidity
Asset Turnover
0.99×
Revenue per ₹ of assets
Revenue CAGR (3Y)
5.3%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹388.15
Bear case
₹234.75
MoS -65.3%
Base case
₹422.77
MoS +8.2%
Bull case
₹492.91
MoS +21.3%
Ratio Trends
THYROCARE · last 7 annual periods
ROE
16.7%
ROCE
35.6%
Operating Margin
—
Debt / Equity
0.05×
PE
547.8×
EV / EBITDA
52.6×
Historical Financials
THYROCARE · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹495 Cr | ₹589 Cr | ₹136 Cr | ₹141 Cr | ₹687 Cr | +8.6% |
| EBITDA | — | ₹264 Cr | ₹130 Cr | ₹147 Cr | ₹204 Cr | -6.3% |
| EBIT | ₹153 Cr | ₹230 Cr | ₹17.6 Cr | ₹26.0 Cr | — | -35.8% |
| PAT | ₹113 Cr | ₹176 Cr | ₹12.5 Cr | ₹19.2 Cr | ₹91.5 Cr | -5.2% |
| EPS (diluted) | ₹21.37 | ₹33.24 | ₹2.36 | ₹3.63 | — | -35.8% |
| CFO | ₹116 Cr | ₹267 Cr | ₹129 Cr | ₹155 Cr | ₹191 Cr | +13.3% |
| CapEx | — | — | — | — | ₹-44.9 Cr | — |
| FCF | — | — | — | — | ₹146 Cr | +0.0% |
| Total Assets | — | ₹608 Cr | ₹633 Cr | ₹620 Cr | ₹693 Cr | +3.3% |
| Total Debt | — | — | ₹0.0 Cr | ₹8.9 Cr | ₹24.7 Cr | — |
| Shareholders' Equity | — | — | ₹534 Cr | ₹514 Cr | ₹547 Cr | +0.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
THYROCARE vs 3 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| METROPOLIS Metropolis Healthcare Limited | -40.3% | 43 | Overvalued | 10.9% | — |
| VIJAYA VIJAYA | — | — | Pending | 17.9% | — |
| SYNGENE Syngene International Limited | -41.7% | 43 | Overvalued | 10.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for THYROCARE in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. THYROCARE TECH LTD (THYROCARE.NS) trades at 388.15 vs a model fair value of 422.77, a gap of 8.9%. Piotroski F-score: 8/9. Moat label: Wi...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of THYROCARE →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for THYROCARE →
Compare
Head-to-head with peers
Compare THYROCARE side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse THYROCARENow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.